RA Drug Does Not Alter Cholesterol Ratio

Published Online: Friday, April 1, 2005

Patients taking Remicade (infliximab) for rheumatoid arthritis (RA) showed not only an improvement in their condition but also a dramatic increase in both high-density lipoprotein (HDL; "good") cholesterol and total cholesterol. Researcher Michael T. Nurmohamed, MD, noted that, "contrary to expectations,"these changes do not positively alter the ratio between total cholesterol and HDL cholesterol, referred to as the atherogenic index. "Hence, the favorable effect of infliximab on the cardiovascular risk in patients with rheumatoid arthritis is not mediated through modification of the lipid profile,"said Dr. Nurmohamed.

For the study, the researchers examined 69 patients with RA to determine the short-term effects of infliximab on cholesterol levels. The results of the study showed that total cholesterol rose from 5.2 to 5.6 units after 6 weeks, while HDL cholesterol increased from 1.4 to 1.6. (The findings were published in the Journal of Rheumatology, February 2005.)



Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A